ClinicalTrials.gg
TerminatedNCT02176863FORCEUpdated Dec 5, 2025Results posted

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

A Phase 2/3 interventional study of Flebogamma® 5% DIF and Placebo in Post-polio Syndrome, sponsored by Instituto Grifols, S.A.. Terminated at 21 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Due to Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This was a multicenter, prospective, randomized, placebo-controlled, double-blind, parallel group clinical trial with adaptive dose selection in participants with post-polio syndrome (PPS).

The main purpose of this study was to select a dose of Flebogamma® 5% DIF and confirm the efficacy of the selected Flebogamma® 5% DIF dose by assessing physical performance, as measured by Two-Minute Walk Distance (2MWD) test.

The study consisted of 2 stages, with each stage consisting of a screening period (up to 4 weeks), a treatment period (52 weeks), and a follow-up period (24 weeks).

02

Conditions studied

  • Post-polio Syndrome

Keywords

  • FORCE
  • Post-polio syndrome
  • Flebogamma®
  • Immune Globulin Intravenous
  • IVIG
03

In context

Postpoliomyelitis Syndrome

28 studies on the registry are indexed under Postpoliomyelitis Syndrome; 3 are open to participants now.

This study's enrollment of 191 is above the median of 40 across 19 interventional studies indexed under Postpoliomyelitis Syndrome.

Browse Postpoliomyelitis Syndrome studies →

Lead sponsor

Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with less than 35 kg/m\^2.
  • Participants who meet the clinical criteria for diagnosis of PPS as set by March-of-Dimes.
  • Participants who are ambulatory or are able to walk with a cane or other aids or use a wheelchair (but they are not wheelchair-bound).
  • Participants who have at least 2 newly weakened muscle groups due to PPS (as defined by medical history), with at least 1 of them in a lower extremity, and having a Medical Research Council (MRC) scale score greater than 3 at the Manual Muscle Testing (MMT) performed by the independent assessor at the Screening Visit (SV).
  • Female of must have a negative test for pregnancy (Human chorionic gonadotropin (HCG)-based assay).
  • Female of child-bearing potential and their sexual partners have agreed to practice using a method of proven reliability (i.e., hormonal methods; barrier methods; intrauterine devices methods) to prevent a pregnancy during the course of the clinical trial.
  • Participants must be willing to comply with all aspects of the clinical trial protocol, including blood sampling and long-term storage of extra samples for the entire duration of the study.
  • Participants who are able to walk a 2MWD of at least 50 meters at the SV and Enrollment Visit/Infusion Visit 1 (EV/IV1)
  • Participants who are able to walk a consistent baseline 2 MWD, that is, the difference in 2MWD between the SV and EV/IV1 is not more than 10%.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received human normal immune globulin treatment given by intravenous, subcutaneous, or intramuscular route within the last 3 years.
  • Participants who are not ambulatory (wheelchair-bound individuals).
  • Participants with poor venous access.
  • Participants with intractable pain requiring narcotics or other psychotropic drugs.
  • Participants with a history of anaphylactic reactions or severe reactions to any blood-derived product.
  • Participants with a history of intolerance to any component of the products, such as sorbitol.
  • Participants receiving , except for those who are taking inhaled corticosteroids for asthma.
  • Participants with a documented diagnosis of hyper viscosity or hypercoagulable state or thrombotic complications to polyclonal intravenous immunoglobulin (IVIG) therapy in the past.
  • Participants with a history of recent (within the last year) myocardial infarction, stroke, or uncontrolled hypertension.
  • Participants who suffer from congestive heart failure, embolism, or changes indicative of unstable angina or atrial fibrillation.
  • Participants with a history of chronic alcoholism or illicit drug abuse (addiction) in the preceding 12 months prior to the SV.
  • Participants with active psychiatric illness that interferes with compliance or communication with health care personnel.
  • Participants with depression with scores >30 as assessed by the Center for Epidemiologic Studies Depression (CESD) validated scale.
  • Females who are pregnant or are nursing an infant child.
  • Participants with any medical condition which makes clinical trial participation unadvisable or which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the clinical trial according to the Investigator's judgment.
  • Participants currently receiving, or have received within 3 months prior to the SV, any investigational medicinal product or device.
  • Participants who are unlikely to adhere to the protocol requirements, or are likely to be uncooperative, or unable to provide a storage serum/plasma sample prior to the first investigational drug infusion.
  • Participants with known selective Immune globulin A class (IgA) deficiency and serum antibodies anti-IgA.
  • Participants with renal impairment (i.e., serum creatinine exceeds more than 1.5 times the [ULN]) for the expected normal range for the testing laboratory).
  • Participants with (AST) or alanine aminotransferase (ALT) levels exceeding more than 2.5 times the ULN.
  • Participants with levels \<10 g/dL, levels \<100,000 /mm\^3, white blood cells count \<3.0 k/µL, and erythrocyte sedimentation rate >50 mm/h or twice above normal.
  • Participants with known seropositive to virus (HCV), -1 (HIV-1) and/or Human immunodeficiency virus-2 (HIV-2).
  • Participants with a history of intolerance to fructose.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIF

    Participants received Flebogamma® 5% DIF 2 g/kg of body weight administered via intravenous (IV) infusion over 2 consecutive days (Flebogamma® 5% DIF 1 g/kg infused on Day 1, followed by Flebogamma® 5% DIF 1 g/kg infused on Day 2) every 4 weeks for 52 weeks.

    Biological: Flebogamma® 5% DIF

  • Experimental
    Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF

    Participants received Flebogamma® 5% DIF 1 g/kg of body weight administered via IV infusion on Day 1, followed by 20 mL/kg of matching placebo administered on a separate day, for a total dosing period of 2 consecutive days, every 4 weeks for 52 weeks. The order of 1 g/kg Flebogamma® 5% DIF or matching placebo was randomly determined for each participant and was the same for the participant for all infusion visits during the treatment period.

    Biological: Flebogamma® 5% DIF · Drug: Placebo

  • Placebo comparator
    Stage 1 Arm 3: Placebo

    Participants received matching placebo at a total dose of 40 mL/kg of body weight administered via IV infusion over 2 consecutive days. On Day 1, a dose of 20 mL/kg of matching placebo was given, followed by the second dose of 20 mL/kg of matching placebo on Day 2, administered every 4 weeks for 52 weeks.

    Drug: Placebo

  • Experimental
    Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF

    Participants received Flebogamma® 5% DIF 1 g/kg of body weight administered via IV infusion on Day 1, followed by 20 mL/kg of matching placebo administered on a separate day, for a total dosing period of 2 consecutive days, every 4 weeks for 52 weeks. The order of 1 g/kg of Flebogamma® 5% DIF or matching placebo was randomly determined for each participant and was the same for the participant for all infusion visits during the treatment period.

    Biological: Flebogamma® 5% DIF · Drug: Placebo

  • Placebo comparator
    Stage 2 Arm 2: Placebo

    Participants received matching placebo at a total dose of 40 mL/kg of body weight administered via IV infusion over 2 consecutive days. On Day 1, a dose of 20 mL/kg of matching placebo was given, followed by the second dose of 20 mL/kg of matching placebo on Day 2, administered every 4 weeks for 52 weeks.

    Drug: Placebo

Interventions

  • Human plasma-derived immunoglobulin

    Also known as: immune globulin intravenous (human)

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Physical Performance Assessed by Two-Minute Walk Distance (2MWD) Test

    The 2MWD was used to assess physical performance by measuring the distance that a participant can quickly walk at a self-preferred speed on an indoor flat, hard surface 30 m (100-ft) hallway in a period of 2 minutes. A positive change from baseline indicates improvement (i.e. a patient can walk farther). Increase in distance walked (in meters) indicates improvement.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain

    VAS is a participant self-reported pain scale used to evaluate the pain level in a 24 hours period. The scale consists of a 100 millimeters (mm) scale where 100 mm stands for the worst imaginable pain and zero stands for no pain. Higher scores indicate severe pain. A negative change from baseline indicates improvement. LS mean and 95% (CI) were based on MMRM method.

    Time frame: Baseline to Week 52

  2. Change From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)

    HRQoL SF-36 is participant self-reported survey.It yields 8-scale profile of functional health and well-being as well as physical and mental health summary measures. It consists of the subscales:physical functioning,limitations due to physical health,body pain,general health,vitality,social functioning,emotional problems, and mental health. Each domain score ranges from 0(worst) to 100(best),higher scores reflect better functional status.PCS is a subscale score \& give broader metric of physical HRQoL.PCS score ranges from 0 to 100 and is computed such that mean score of 50 corresponds to the general US population.Based on norm-based scoring,scores above 50 is better-than-average health \& below 50 is below-average health.Higher scores represents better physical health.Positive change from baseline indicates improvement.LS mean and 95% CI were based on MMRM.

    Time frame: Baseline to Week 52

  3. Change From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test

    The 6MWD was used to assess physical performance by measuring the distance that a patient can quickly walk at maximal speed on a flat, hard surface 30 m (100-ft) hallway in a period of 6 minutes. A positive change from baseline indicates improvement (i.e., a patient can walk farther). Increase from baseline in distance walked (in meters) indicated improvement. LS mean and 95% CI were based on MMRM method.

    Time frame: Baseline to Week 52

07

Results

Posted Dec 5, 2025

Participant flow

Participants took part in the study from 23 September 2014 to 24 November 2022.

Participant flow — Overall Study
MilestoneStage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: Placebo
Started4242423332
Completed2534332626
Not completed178976
Withdrew: Physician decision10000
Withdrew: Adverse event104411
Withdrew: Protocol violation20110
Withdrew: Withdrawal by subject42234
Withdrew: Reason not specified01121
Withdrew: Lost to follow-up01100

Outcome measures

PrimaryChange From Baseline in Physical Performance Assessed by Two-Minute Walk Distance (2MWD) Test

The 2MWD was used to assess physical performance by measuring the distance that a participant can quickly walk at a self-preferred speed on an indoor flat, hard surface 30 m (100-ft) hallway in a period of 2 minutes. A positive change from baseline indicates improvement (i.e. a patient can walk farther). Increase in distance walked (in meters) indicates improvement.

Time frame:
Baseline to Week 52
Reported as:
Mean · meters (m)
Change From Baseline in Physical Performance Assessed by Two-Minute Walk Distance (2MWD) Test
meters (m)Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: Placebo
Baseline109.03 ± 30.564112.55 ± 27.987105.86 ± 31.942101.18 ± 22.588107.10 ± 30.167
Change from Baseline at Week 527.50 ± 14.66610.89 ± 19.0673.17 ± 11.08011.31 ± 12.1085.65 ± 10.388
Statistical analysis
  • Stage 1 Arm 2: 1 g/kg Flebogamma® 5% DIF vs Stage 1 Arm 3: Placebo vs Stage 2 Arm 1: 1 g/kg Flebogamma® 5% DIF vs Stage 2 Arm 2: Placebo · Posch and Bauer Method · p = 0.0469 (The overall adjusted p-value for the selected dose of Flebogamma® 5% DIF vs placebo was calculated from the p-values of both Stage 1 and Stage 2 by Posch \& Bauer for testing the equality of means between the selected dose and placebo.)
SecondaryChange From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain

VAS is a participant self-reported pain scale used to evaluate the pain level in a 24 hours period. The scale consists of a 100 millimeters (mm) scale where 100 mm stands for the worst imaginable pain and zero stands for no pain. Higher scores indicate severe pain. A negative change from baseline indicates improvement. LS mean and 95% (CI) were based on MMRM method.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · millimeter (mm)
Change From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain
millimeter (mm)Flebogamma® 5% DIF 1 g/kgPlacebo
Change From Baseline in Pain Using Visual Analogue Scale (VAS) of Pain-3.2 (-10.4 to 4.1)-2.6 (-9.9 to 4.6)
Statistical analysis
  • Flebogamma® 5% DIF 1 g/kg vs Placebo · Mixed-effect Model Repeated Measures · p = 0.8897 (MMRM include change from baseline in VAS as dependent variable;treatment,protocol-specified visit,treatment-by-visit interaction,main part affected(fixed effect);baseline as covariate \& measures within-participants at each visit(repeated measure).) · Ls mean difference: -0.5 · 95% CI -7.7 to 6.7
SecondaryChange From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)

HRQoL SF-36 is participant self-reported survey.It yields 8-scale profile of functional health and well-being as well as physical and mental health summary measures. It consists of the subscales:physical functioning,limitations due to physical health,body pain,general health,vitality,social functioning,emotional problems, and mental health. Each domain score ranges from 0(worst) to 100(best),higher scores reflect better functional status.PCS is a subscale score \& give broader metric of physical HRQoL.PCS score ranges from 0 to 100 and is computed such that mean score of 50 corresponds to the general US population.Based on norm-based scoring,scores above 50 is better-than-average health \& below 50 is below-average health.Higher scores represents better physical health.Positive change from baseline indicates improvement.LS mean and 95% CI were based on MMRM.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)
Score on a scaleFlebogamma® 5% DIF 1 g/kgPlacebo
Change From Baseline in Health-Related Quality of Life (HRQoL) Assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)4.78 (1.9 to 7.6)2.79 (-0.1 to 5.7)
Statistical analysis
  • Flebogamma® 5% DIF 1 g/kg vs Placebo · Mixed-effect Model Repeated Measures · p = 0.1615 (MMRM include change from baseline in SF-36PCS as dependent variable;treatment protocol-specified visit,treatment-by-visit interaction,main part affected(fixed effect);baseline measure as covariate \& within-participant at each visit(repeated measure).) · Ls mean difference: 1.98 · 95% CI -0.8 to 4.8
SecondaryChange From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test

The 6MWD was used to assess physical performance by measuring the distance that a patient can quickly walk at maximal speed on a flat, hard surface 30 m (100-ft) hallway in a period of 6 minutes. A positive change from baseline indicates improvement (i.e., a patient can walk farther). Increase from baseline in distance walked (in meters) indicated improvement. LS mean and 95% CI were based on MMRM method.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · meters (m)
Change From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test
meters (m)Flebogamma® 5% DIF 1 g/kgPlacebo
Change From Baseline in Endurance Assessed by Six-Minute Walk Distance (6MWD) Test29.16 (7.54 to 50.78)13.36 (-8.22 to 34.95)
Statistical analysis
  • Flebogamma® 5% DIF 1 g/kg vs Placebo · Mixed-effect Model Repeated Measures · p = 0.1205 (MMRM include change from baseline in 6MWD as dependent variable;treatment,protocol-specified visit,treatment-by-visit interaction,main part affected(fixed effect);baseline as covariate \& measures within-participants at each visit(repeated measure).) · Ls mean difference: 15.80 · 95% CI -4.19 to 35.79

Adverse events

Collected over From the start of study drug administration through 4 weeks after last study treatment (Up to Week 56). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flebogamma® 5% DIF 2 g/kg0/42 (0%)3/42 (7.1%)36/42 (85.7%)
Flebogamma® 5% DIF 1 g/kg0/75 (0%)7/75 (9.3%)71/75 (94.7%)
Placebo0/74 (0%)9/74 (12.2%)60/74 (81.1%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventFlebogamma® 5% DIF 2 g/kgFlebogamma® 5% DIF 1 g/kgPlacebo
HypertensionVascular disorders0/420/752/74
PneumoniaInfections and infestations0/420/752/74
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/420/750/74
Myocardial infarctionCardiac disorders1/420/750/74
PyelonephritisInfections and infestations1/420/750/74
Miscarriage of partnerSocial circumstances0/420/751/74
Ankle fractureInjury, poisoning and procedural complications0/420/751/74
Bone fissureInjury, poisoning and procedural complications0/420/751/74
SyncopeNervous system disorders0/420/751/74
Food poisoningGastrointestinal disorders0/420/751/74
Most frequent other events
Showing 10 of 42
Most frequent other events
EventFlebogamma® 5% DIF 2 g/kgFlebogamma® 5% DIF 1 g/kgPlacebo
HeadacheNervous system disorders27/4239/7523/74
FatigueGeneral disorders14/4222/7520/74
NauseaGastrointestinal disorders11/4213/754/74
ChillsGeneral disorders8/4215/752/74
PyrexiaGeneral disorders8/4213/751/74
ArthralgiaMusculoskeletal and connective tissue disorders8/4212/7512/74
DizzinessNervous system disorders3/424/7513/74
HypertensionVascular disorders7/4212/758/74
NasopharyngitisInfections and infestations4/428/7511/74
RashSkin and subcutaneous tissue disorders1/4211/750/74

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: PlaceboTotal
Mean63.3 ± 6.2462.3 ± 6.8862.2 ± 7.2265.1 ± 7.0063.9 ± 6.2663.2 ± 6.76
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: PlaceboTotal
Female2321272222115
Male192115111076
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: PlaceboTotal
Hispanic or Latino3664120
Not Hispanic or Latino3936362931171
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1 Arm 1: 2 g/kg Flebogamma® 5% DIFStage 1 Arm 2: 1 g/kg Flebogamma® 5% DIFStage 1 Arm 3: PlaceboStage 2 Arm 1: 1 g/kg Flebogamma® 5% DIFStage 2 Arm 2: PlaceboTotal
American Indian or Alaska Native000000
Asian221106
Native Hawaiian or Other Pacific Islander000000
Black or African American001102
White4040403131182
More than one race000000
Unknown or Not Reported000011
08

Study locations

21 sites
  • Washington University
    St Louis, Missouri 63110, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226-3596, United States
  • Montreal Neurological Institute Clinical Research Unit, McGill University
    Montreal, Quebec H3A 2B4, Canada
  • Thomayerova nemocnice, Klinicko-farmakologická jednotka
    Prague, 4, Czechia
  • Aarhus Universitets Hospital-Neurologisk Forskning
    Aarhus N, 8200, Denmark
  • Rigshospitalet
    København Ø, 2100, Denmark
  • Charité Campus Mitte
    Berlin, 10117, Germany
  • Hannover Medical School
    Hanover, 30625, Germany
  • Universitätsklinikum Jena
    Jena, 07747, Germany
  • Klinik für konservative Orthopädie und des Poliozentrums
    Koblenz, 56073, Germany
  • Westfälische Wilhelms-Universität Münster
    Münster, 48149, Germany
  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
    Verona, 37124, Italy
  • Academisch Medisch Centrum Amsterdam UMC, Locatie AMC
    Amsterdam, 1105 AZ, Netherlands
  • MedTrials
    Krakow, 31-436, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
    Lublin, 20-954, Poland
  • Clinical Research Center Sp. z o.o.
    Poznan, 60-848, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny
    Warsaw, 02-097, Poland
  • Institut Guttman
    Badalona, 08916, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Nov 2022, 98 months.

Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Nov 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 27, 2014
StartActual
Sep 23, 2014
Primary completionActual
Nov 24, 2022
CompletionActual
Nov 24, 2022
Results delay requested
Nov 23, 2023
Results first posted
Dec 5, 2025
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02176863
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Sep 23, 2014
Primary completion
Nov 24, 2022
Completion
Nov 24, 2022
Results posted
Dec 5, 2025
Last update
Dec 5, 2025

Study contacts

Marinos Dalakas, MD
principal investigator · Coordinating Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion